Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer by unknown
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Zhang et al. World Journal of Surgical Oncology 2013, 11:286
http://www.wjso.com/content/11/1/286RESEARCH Open AccessFactors associated with receipt of adjuvant
chemotherapy among married women with
breast cancer
Yan Zhang1, Hua Gao2, Yulan Bu1, Xiuzhen Fan1* and Jihui Jia1*Abstract
Background: Adjuvant chemotherapies are recommended for most women after breast cancer surgery, and can
greatly affect the patients’ survival. We describe and evaluate possible factors influencing receipt of postoperative
adjuvant chemotherapy among breast cancer patients in China.
Methods: A total of 1,431 women diagnosed with breast cancer from 1997 to 2005 were enrolled. We reviewed
medical records and abstracted information about these patients. Details on social-demographic factors and
clinical-pathological characteristics of participants were collected and analyzed. To meet our objectives, the patient’s
age at diagnosis, comorbidities, menstrual status, rural/urban status, tumor size, lymph node status, distant metasta-
sis, tumor stage and hormone receptor status were estimated.
Results: Overall, 936 of these 1,431 patients (65.41%) received adjuvant chemotherapy. Receipt of chemotherapy
was significantly associated with age at diagnosis, rural–urban disparities, and lymph node status of patients,
though no significant difference was found between the age <50 and age 50 to 64 groups. Moderate association
was also observed between hormone receptor status and receipt of adjuvant chemotherapy, though it was still not
statistically significant.
Conclusions: Our study suggests that age at diagnosis, rural–urban disparities and lymph node status of breast
cancer patients are independent predictors for receipt of adjuvant chemotherapy among married Chinese women.
Further investigations are warranted, and related public health education needs to be expanded in China.
Keywords: Breast cancer, Adjuvant chemotherapy, Epidemiology, Neoadjuvant chemotherapyBackground
Breast cancer has become the leading cause of cancer
death among women in developing countries (for ex-
ample, China), as well as the most diagnosed malignant
tumor [1]. There are multiple strategies for breast cancer
treatment, and adjuvant chemotherapy shows great
benefit in reducing disease recurrence and improving
prognosis for postoperative breast cancer patients [2,3].
Adjuvant chemotherapy is given after initial treatment
with surgery, and is considered standard treatment for
breast cancer patients [4-6]. Several studies have re-
vealed that race, as well as marital status, may impact* Correspondence: fxiuzhen@sdu.edu.cn; jiajihui@sdu.edu.cn
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reproduction in any medium, provided the orthe receipt or completion of adjuvant chemotherapy
among breast cancer patients [7-9]. We describe and
evaluate possible factors influencing receipt of postoper-
ative adjuvant chemotherapy among married yellow-race
women with breast cancer in China.Methods
Patients and data collection
Females diagnosed with primary breast cancer between
1 January 1 1997 and 31 December 2005 and who re-
ceived surgery treatment post-diagnosis in Qilu Hospital
were collected as candidates. All cases are yellow race,
married females who met clinical criteria for consi-
deration of adjuvant chemotherapy. We retrieved and
identified information from medical records. To meet
our objectives, social-demographic factors and clinical-Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tient’s age at diagnosis, comorbidities, menstrual status,
rural/urban status, tumor size, lymph node status, dis-
tant metastasis, tumor stage, hormone receptor status,
race, marital status, and others were abstracted.
Breast cancer cases were identified by operation and
histopathological examination. Clinical-pathological pa-
rameters such as estrogen receptor (ER) and progesto-
gen receptor (PR) were evaluated by immunological
histological chemistry staining. Cases were scored posi-
tive when ≥10% of the tumor cells on the slide showed
positive staining irrespective of staining intensity. Oper-
ating procedures were classified into radical mastectomy,
modified radical mastectomy and breast/nipple conserving
surgery. Rurality was defined according to the socioeco-
nomic survey team of the National Bureau of Statistics of
China [10]. Comorbid illness includes cardiovascular dis-
eases, rheumatism, tuberculosis, liver disease and other
chronic diseases excluding previous or current malignant
tumors that were reported by patients or their relatives.
Patients without menses for more than six months were
classified as postmenopausal cases. All variables were
measured as of the time of treatment. Studies have shown
that receipt of neoadjuvant chemotherapy may influence
decisions about adjuvant chemotherapy [7,11,12]. As a re-
sult, whether a patient had received neoadjuvant chemo-
therapy was identified and classified.
Data collection was performed independently by two
individuals. Patients’ information was abstracted and
coded anonymously for all participants in the study.
Written, informed consent was obtained as delineated
by the protocol, which was approved by the ethical com-
mittee of Shandong University.
Statistical analyses
We conducted univariate analyses with each of these ex-
planatory variables using Chi-square (χ2) tests accom-
panied by two-sided P values. A multivariate logistic
regression model evaluated the association between pre-
dictors and receipt of adjuvant chemotherapy. Because
the factors that affect delivery of neoadjuvant chemo-
therapy are probably similar to those that affect adjuvant
chemotherapy, we removed parameters of neoadjuvant
chemotherapy from the multivariate analyses. Logistic
regression outcomes were expressed as adjusted odds
ratios (OR), with 95% confidence intervals (CI). For
estrogen receptor/progestogen receptor (ER/PR) status,
the predictor variable showed a significant number of
missing values; therefore, we re-estimated the relevant
model as a sensitivity test. All the statistics were per-
formed using the PASW Statistics 18.0 software (SPSS
Inc. Chicago, Illinois, USA), and were based on two-
tailed probability. P values of <0.05 were considered
statistically significant.Results
During the period from 1 January 1997 to 31 December
2005, a total of 1,431 married women who were diag-
nosed with invasive breast cancer (pTNM stage I - IV)
and who received breast surgery in Qilu Hospital was in-
cluded in our analyses. Overall, 936 of these 1,431 pa-
tients (65.41%) received adjuvant chemotherapy, and
patients’ social-demographic and clinical-pathological
characteristics were described in Table 1. We included
possible predictors into our univariate analyses, as
shown in Table 2. The percentage of rural women who
received chemotherapies was significantly lower when
compared with urban females (61.15% versus 67.38%,
P = 0.021). Meanwhile, our results showed that receipt
of chemotherapy was significantly associated with pa-
tient’s age at diagnosis (P = 0.030), with older females
receiving less adjuvant chemotherapy. Whether a patient
received neoadjuvant chemotherapy was related to the
final decision of receipt of adjuvant chemotherapy or
not (P <0.001). Importantly, outcomes demonstrated
that lymph node status of patients was highly associated
with their final decision about receipt of adjuvant che-
motherapy (P <0.001). In these unadjusted analyses, no
significant association was found between comorbid
status, menopausal status, tumor size, distant metastasis
or tumor stage and receipt of chemotherapy. Moderate
association was observed between hormone receptor sta-
tus and receipt of chemotherapy, with a P value of 0.082.
Then we estimated the adjusted values by controlling
covariates using multivariate logistic regression model,
as shown in Table 3. Interestingly, the statistical pattern
of result did not change, and the significant association
demonstrated in the univariate analyses still existed in
the multivariate analyses, with the exception of neo-
adjuvant status, a parameter that had been removed
from the analytic models. Receipt of chemotherapy was
significantly associated with age at diagnosis, rural–
urban disparities, and lymph node status of patients.
The difference between age <50 and age ≥70 was signifi-
cant (OR = 0.407, 95% CI = 0.209 to 0.792, P =0.008),
though no significant difference was found between age
<50 and age 50 to 64 groups (P = 0.319). More urban
females received adjuvant chemotherapy than rural ones
after adjusting r other parameters (OR = 1.381, 95%
CI = 1.083 to 1.761, P = 0.009). Patients with positive
lymph node metastases received adjuvant chemotherapy
more often than patients with negative cases of lymph
node metastases (OR = 1.600, 95% CI = 1.266 to 2.022,
P <0.001). Moderate association was also observed be-
tween hormone receptor status and receipt of adjuvant
chemotherapy, though it was still not statistically signifi-
cant (P = 0.066). Because ER/PR status is an important
pathological factor and because observations on this
variable were missing for 38.71% of the cases, we
Table 1 Demographic and clinical characteristics of breast
cancer patients
Variable Number of cases (N = 1,431)
Age at diagnosis (years)
<50 780















Previous or current 13



















ER- and PR- 203









Modified radical mastectomy 828








ER, estrogen receptor; PR, progestogen receptor; IDC, invasive ductal
carcinoma; ILC, invasive lobular carcinoma; NOS, not otherwise specified.
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shown). We re-estimated the logistic regression model
(1) by excluding hormone receptor (ER/PR) status or (2)
by only accepting the remaining 887 patients with ER/
PR information. No change in sign or patterns of statis-
tical significance was found for any of them.
Previous studies have mentioned that receipt of neoad-
juvant chemotherapy could influence a patient’s deci-
sions about receipt of adjuvant chemotherapy [7,11,12].
Consequently, we excluded patients who had received
neoadjuvant chemotherapy (as have other studies men-
tioned above) and re-estimated the logistic regression
model in Table 4. Overall, 1,075 patients were included,
and there were no changes in sign or patterns of statis-
tical significance for any of the parameters. Because the
factors that affect delivery of neoadjuvant chemotherapy
are probably similar to those that affect adjuvant che-
motherapy, and because women get all of their che-
motherapy as neoadjuvant in some countries, we also
re-estimate our analytic model by combining neoadjuvant
and/or adjuvant chemotherapy as dependent variables, as
shown in Table 5. A moderately significant association
was observed between rural–urban disparities and receipt
of adjuvant chemotherapy, with a P value of 0.072. No
changes in sign or patterns of statistical significance were
observed for the remaining factors.
All the logistic regression models adopted in this study
exhibited high goodness-of-fit, with a Hosmer-Lemeshow
goodness-of-fit P value of 0.996 in Table 3 and above
0.500 in all logistic models.
Discussion
Receipt of proper adjuvant chemotherapy for breast can-
cer patients is very important and associated with prog-
nosis of breast cancer patients. Both clinical trials and
Table 2 Univariate analysis of demographic and clinical








Age at diagnosis (years)
<50 780 79.62% 0.030




No 1,075 60.28% <0.001
Yes 356 80.90%
Comorbidities
None 1,024 65.43% 0.979
One or more 407 65.36%
Menopausal status
Premenopause 703 66.29% 0.492
Menopause 728 64.56%
Residential status
Rural 453 61.15% 0.021
Urban 978 67.38%
Tumor size
≤2 1,088 67.2% 0.369
>2 214 64.0%
Lymph node metastasis
Negative 823 61.6% <0.001
Positive 606 70.6%
Distant metastasis
Negative 1,421 65.4% 0.759
Positive 10 70.0%
Tumor stage





ER- and PR- 203 61.58% 0.082
ER + and/or PR+ 648 71.91%
ER, estrogen receptor; PR, progestogen receptor.
Table 3 Logistic regression analysis of demographic and
clinical factors associated with receipt of adjuvant
chemotherapy
Variable ORa 95% CIa Adjusted Pa
Age at diagnosis (years)
<50 Referent
50 to 69 0.769 0.463 to 1.275 0.308
≥70 0.410 0.212 to 0.793 0.008
Comorbidities
None Referent
One or more 1.033 0.791 to 1.349 0.811
Menopausal status
Premenopause Referent
Menopause 1.205 0.734 to 1.979 0.461
Residential status
Rural Referent
Urban 1.381 1.083 to 1.761 0.009
Tumor size
≤2 Referent
>2 0.828 0.603 to 1.136 0.242
Lymph node metastasis
Negative Referent
Positive 1.600 1.266 to 2.022 <0.001
Distant metastasis
Negative Referent
Positive 1.123 0.282 to 4.475 0.869
Hormone receptor status
ER- and PR- Referent
ER + and/or PR+ 1.364 0.979 to 1.900 0.066
aAdjusted using multivariate logistic regression model.
ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI,
confidence intervals.
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with breast cancer who are able to gain benefit from ad-
juvant chemotherapy [4,13-15]. Many factors, including
age, comorbidities, marital status, variation in provider
recommendation, medical insurance, and life expect-
ancy, are associated with whether women receive adju-
vant chemotherapy and have been reported for a long
time [12,16-20]. Married women usually enjoy overallbetter health and higher socioeconomic status than
unmarried ones, which may translate into better access
to healthcare and other benefits. Meanwhile, marriage
may reflect a healthy selection bias, and one study has
reported that those with psychiatric or physical im-
pairments may be less likely to marry [21]. Marriage may
also influence the lifestyle and behaviors of women,
including diet, exercise, and health screening, which may
be mediating factors when making better medical choices
[22]. On the other hand, marriage could offer better social
support networks [23], indicating better financial support
and receipt of more sensible advice, which could influence
a woman’s choice about receipt of adjuvant chemotherapy.
Considering that most of our candidates were married,
this study only focused on married women to reduce bias
resulting from these confounding factors. Our research
focused on married Chinese women who met clinical
Table 4 Logistic regression analysis of factors associated
with receipt of adjuvant chemotherapy among patients
not receiving neoadjuvant chemotherapy
Variable ORa 95% CIa Adjusted Pa
Age at diagnosis (years)
<50 Referent
50 to 69 0.690 0.386 to 1.234 0.211
≥70 0.303 0.143 to 0.643 0.002
Comorbidities
None Referent
One or more 1.090 0.810 to 1.467 0.568
Menopausal status
Premenopause Referent
Menopause 1.374 0.778 to 2.428 0.274
Residential status
Rural Referent
Urban 1.398 1.058 to 1.846 0.018
Tumor size
≤2 Referent
>2 0.799 0.510 to 1.150 0.198
Lymph node metastasis
Negative Referent
Positive 1.383 1.057 to 1.809 0.018
Distant metastasis
Negative Referent
Positive 1.908 0.191 to 19.015 0.582
Hormone receptor statusa
ER- and PR- Referent
ER + and/or PR+ 1.425 0.981 to 2.070 0.063
aAdjusted using multivariate logistic regression model.
ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI,
confidence intervals.
Table 5 Logistic regression analysis of demographic and
clinical factors associated with receipt of adjuvant and/or
neoadjuvant chemotherapy
Variable ORa 95% CIa Adjusted Pa
Age at diagnosis (years)
<50 Referent
50 to 69 0.701 0.407 to 1.207 0.200
≥70 0.337 0.169 to 0.674 0.002
Comorbidities
None Referent
One or more 1.075 0.813 to 1.420 0.613
Menopausal status
Premenopause Referent
Menopause 1.319 0.773 to 2.249 0.310
Residential status
Rural Referent
Urban 1.265 0.979 to 1.633 0.072
Tumor size
≤2 Referent
>2 1.266 0.888 to 1.804 0.192
Lymph node metastasis
Negative Referent
Positive 1.933 1.508 to 2.477 <0.001
Distant metastasis
Negative Referent
Positive 2.639 0.326 to 21.335 0.363
Hormone-receptor status
ER- and PR- Referent
ER + and/or PR+ 1.392 0.986 to 1.964 0.060
aAdjusted using multivariate logistic regression model.
ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI,
confidence intervals.
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sible predictors about receipt of adjuvant chemotherapy.
Though the recommendations and protocols for adjuvant
chemotherapy changed over this period, an inpatient who
was recommended for chemotherapy but refused doctors’
advice would be recorded for the purpose of preventing
medical accidents, so we were able to select candidates for
this study. For now, only patients with invasive breast can-
cers are recommended for adjuvant chemotherapy gener-
ally, and we performed secondary selection only accepting
patients diagnosed with invasive breast cancers, in line
with current research. Because health care in China is a
government-run project and most of our patients on rec-
ord were covered by this basic medical insurance system,
we did not take individual financial income of breast can-
cer patients into consideration.In the univariate analyses, we found that 65.41% of the
patients in this research have received postoperative
adjuvant chemotherapy. Age at diagnosis, rural–urban
disparities, and receipt of neoadjuvant chemotherapy or
not, significantly associated with the final decision of
patients about the receipt of adjuvant chemotherapy, as
shown in Table 2. After being controlled for covariates, the
differences still existed and no change in sign or patterns of
statistical significance was observed in all participants and
cases without receipt of neoadjuvant chemotherapy only, as
shown in Table 3 and Table 4, respectively.
Age of patients is associated with receipt of adjuvant
chemotherapy and has been studied for a long time
[3,11,16,24-26]. Our data revealed that older women
adopt adjuvant chemotherapy less than young women,
especially women at least 70 years old. In the clinic,
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and more likely to adopt more conservative treatment
for a better quality of remaining life, consistent with
clinical reports and consensus guidelines [14,24,27].
We also found that more urban women adopted adju-
vant chemotherapy than rural ones, and the differ-
ence is statistically significant. Rural–urban disparities
have an influence on many aspects for Chinese fe-
males, especially on education, life style, income and
so forth, and urban women usually receive a better
education and make more money. All of these could
result in urban women knowing the benefit of adju-
vant chemotherapy better, being more willing and
able to pay for their health, and being able to endure
the pain and chemotherapy.
As mentioned in previous studies, receipt of neoadjuvant
chemotherapy may influence the decisions about adjuvant
chemotherapy [7,11]. Our results indicate that patients who
received neoadjuvant chemotherapy are more likely to
receive postoperative chemotherapy (80.90% versus 60.28%,
P <0.001). Because the factors that affect delivery of neo-
adjuvant chemotherapy are probably similar to those that
affect adjuvant chemotherapy, we re-estimated the pre-
dictors among females without receipt of neoadjuvant
chemotherapy or combined neoadjuvant and/or adjuvant
chemotherapy as one dependent variable. After that we still
had similar results, which verify the predictors discovered
in our analyses.
Strengths and weaknesses
First, chemotherapy regimens adopted by patients in our
study consist of CMF, CTX, CEF and so forth, and we
did not include chemotherapy regimens as parameters
in our analyses. However, it would make our analytic
models overly complicated and affect the accuracy and
stability of our results since many patients accepted
chemotherapy with multiple regiments. Second, a signifi-
cant number of predictor values (ER and PR status) were
missing in the multivariate analytic models. Nonetheless,
we re-estimated the relevant model by excluding
hormone-receptor (ER/PR) status or by only accepting
the remaining 887 patients with ER/PR information in
the analyses, and found no change in sign or patterns of
statistical significance for any of them.
Conclusions
Recently the importance of understanding patients who
did or did not receive advised adjuvant chemotherapy
was highlighted and discussed [3,7,8]. Studies have dis-
covered that whether a patient who met clinical criteria
for adjuvant chemotherapy accepted it or not, is associ-
ated with human race, marital status, socioeconomic
status, and some other demographic factors. In this
study, we collected information on female breast cancerpatients who are yellow race and married, and explored
the predictors about receipt of adjuvant chemotherapy.
Our study suggests that age at diagnosis, rural–urban
disparities and lymph node status of breast cancer
patients are independent predictors for the receipt of
adjuvant chemotherapy among married Chinese women.
Further investigations are warranted, and related public
health education needs to be expanded in China.
Abbreviations
CI: Confidence interval; ER: Estrogen receptors; IDC: Invasive ductal
carcinoma; ILC: Invasive lobular carcinoma; NOS: Not otherwise specified;
OR: Odds ration; PR: Progestogen receptor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YZ, XF and JJ conceived of the study and drafted and revised the
manuscript. YZ, HG and YB carried out the data collection and the statistical
analysis. All authors read and approved the final manuscript.
Acknowledgements
We thank all medical staff in the Department of Breast Surgery, Qilu Hospital,
for support and critical discussions.
Author details
1Department of Nursing, Qilu Hospital and School of Nursing, Shandong
University, West Wenhua Road, Ji'nan, Shandong 250012, P.R China.
2Tianchen Hospital of Zaozhuang Mining Group, Tianchen Town, Zaozhuang
City 277500, P.R China.
Received: 14 January 2013 Accepted: 18 October 2013
Published: 31 October 2013
References
1. Jemal A, Bray F, Melissa M, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Bonadonna G, Valagussa P: Dose–response effect of adjuvant
chemotherapy in breast cancer. N Engl J Med 1981, 304:10–15.
3. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB,
Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD,
Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G,
Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB
Investigators: Adjuvant chemotherapy in older women with early-stage
breast cancer. N Engl J Med 2009, 360:2055–2065.
4. Consensus NIH: Statement. Adjuvant Therapy for Breast Cancer 2000, 17:1–35.
5. Consensus conference: Adjuvant chemotherapy for breast cancer.
JAMA 1985, 254:3461–3463.
6. NIH consensus conference: Treatment of early-stage breast cancer.
JAMA 1991, 265:391–395.
7. Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB,
Ward KC: Black-white differences in receipt and completion of adjuvant
chemotherapy among breast cancer patients in a rural region of the US.
Breast Cancer Res Treat 2012, 133:285–296.
8. Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK,
Livingston RB, Albain KS: Treatment quality and outcomes of African
American versus white breast cancer patients: retrospective analysis of
Southwest Oncology studies S8814/S8897. J Clin Oncol 2009, 27:2157–2162.
9. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J,
Guth AA: Missed opportunities: racial disparities in adjuvant breast
cancer treatment. J Clin Oncol 2006, 24:1357–1362.
10. China. SstoNBoSo: Fifty years of cities of People’ s Republic of China. Beijing:
Xinhua Press; 1999.
11. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS: Use and
outcomes of adjuvant chemotherapy in older women with breast
cancer. J Clin Oncol 2006, 24:2750–2756.
12. Richardson LC, Tian L, Voti L, Hartzema AG, Reis I, Fleming LE, Mackinnon J:
The roles of teaching hospitals, insurance status, and race/ethnicity in
Zhang et al. World Journal of Surgical Oncology 2013, 11:286 Page 7 of 7
http://www.wjso.com/content/11/1/286receipt of adjuvant therapy for regional-stage breast cancer in Florida.
Am J Public Health 2006, 96:160–166.
13. Glick JH, Gelber RD, Goldhirsch A, Senn HJ: Adjuvant therapy of primary
breast cancer. 4th International Conference on Adjuvant Therapy of
Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol 1992, 3:801–807.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights:
international consensus panel on the treatment of primary breast
cancer. Seventh international conference on adjuvant therapy of primary
breast cancer. J Clin Oncol 2001, 19:3817–3827.
15. Rao RD, Cobleigh MA: Adjuvant endocrine therapy for breast cancer.
Oncology (Williston Park) 2012, 26:541–547. 550, 552 passim.
16. Silliman RA, Guadagnoli E, Weitberg AB, Mor V: Age as a predictor of
diagnostic and initial treatment intensity in newly diagnosed breast
cancer patients. J Gerontol 1989, 44:M46–M50.
17. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS: Discrepancy between
consensus recommendations and actual community use of adjuvant
chemotherapy in women with breast cancer. Ann Intern Med 2003,
138:90–97.
18. Bickell NA, Aufses AH Jr, Chassin MR: The quality of early-stage breast
cancer care. Ann Surg 2000, 232:220–224.
19. Breen N, Wesley MN, Merrill RM, Johnson K: The relationship of socio-economic
status and access to minimum expected therapy among female breast
cancer patients in the National Cancer Institute Black-White Cancer Survival
Study. Ethn Dis 1999, 9:111–125.
20. Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast
cancer treatment and survival. J Natl Cancer Inst 2002, 94:490–496.
21. Kisker EE, Goldman N: Perils of single life and benefits of marriage.
Soc Biol 1987, 34:135–152.
22. Kravdal O: The impact of marital status on cancer survival. Soc Sci Med
2001, 52:357–368.
23. Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P: Sources of support
and the physical and mental well-being of young women with breast
cancer. Soc Sci Med 2001, 53:1513–1524.
24. Du X, Goodwin JS: Patterns of use of chemotherapy for breast cancer in
older women: findings from Medicare claims data. J Clin Oncol 2001,
19:1455–1461.
25. Buist DS, Chubak J, Prout M, Yood MU, Bosco JL, Thwin SS, Gold HT, Owusu C,
Field TS, Quinn VP, Wei F, Silliman RA: Referral, receipt, and completion of
chemotherapy in patients with early-stage breast cancer older than 65 years
and at high risk of breast cancer recurrence. J Clin Oncol 2009, 27:4508–4514.
26. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P,
Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases
prognosis of breast cancer in elderly women. J Clin Oncol 2003,
21:3580–3587.
27. Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL,
Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R,
Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H, Cancer
Leukemia Group B: Breast cancer adjuvant chemotherapy decisions in
older women: the role of patient preference and interactions with
physicians. J Clin Oncol 2010, 28:3146–3153.
doi:10.1186/1477-7819-11-286
Cite this article as: Zhang et al.: Factors associated with receipt of
adjuvant chemotherapy among married women with breast cancer.
World Journal of Surgical Oncology 2013 11:286.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
